$3.46
-2.1%Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
NAGE • NASDAQ
| Niagen Bioscience Inc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Nov 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||||||
17.4M | 8.6M | -4.9M | -16.5M | -27.1M | -19.9M | -32.1M | -33.3M | -11.4M | -2.9M | -2.8M | -5.4M | -4.4M | -11.7M | -7.9M | -2.1M | -907.6K | -2.1M | -38.4K | |
1.5M | 1.5M | 1.7M | 1.9M | 1.6M | 1.5M | 1.5M | 842K | 716K | 419.6K | 330.6K | 258.3K | 269.7K | 344K | 398.9K | 387.4K | 394.5K | 376.3K | 0.0 | |
0.0 | 3.7M | 4.8M | 5.7M | 6.2M | 6.9M | 7.2M | 6.4M | 4.6M | 1.2M | 2M | 2.9M | 1.3M | 2.7M | 3M | 1.3M | 205.9K | 121.2K | 0.0 | |
2.9M | -4.7M | 977K | -167K | -124K | -204K | 2.6M | 4K | -5.8M | 1.1M | 557.4K | 144.5K | -330K | 1.9K | 133.5K | 20.6K | -554.0 | 33.1K | 0.0 | |
-8.3M | 3.1M | 4.6M | -6M | -4.7M | 1.1M | 427K | 5.2M | 2M | -2.8M | -2.2M | -512K | -714.1K | -1.5M | 294.6K | -2.3M | -88.4K | -347.4K | -101.0 | |
13.4M | 12.1M | 7.1M | -15.1M | -24.2M | -10.6M | -20.4M | -20.9M | -9.8M | -2.9M | -2.1M | -2.6M | -3.9M | -10.1M | -4.1M | -2.7M | -396.2K | -1.9M | -38.5K | |
INVESTING ACTIVITIES | |||||||||||||||||||
-292K | -163K | -148K | -334K | -409K | -124K | -743K | -1.3M | -1.2M | -1.5M | -525.2K | -121.7K | -137.3K | -24.6K | -150.7K | -169.1K | -184.5K | -417.5K | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.8M) | (225K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 20K | 5K | 0.0 | 0.0 | -41K | 494K | -454K | 5.8M | -220K | -122.5K | -130K | 911K | -52K | -26K | -30K | 5K | -78.3K | 0.0 | |
-292K | -143K | -143K | -334K | -409K | -165K | -249K | -1.8M | (4.6M) | -1.7M | -647.7K | (1.6M) | (998.7K) | -76.6K | -176.7K | -199.1K | -179.5K | -495.8K | (0.0) | |
FINANCING ACTIVITIES | |||||||||||||||||||
7M | 5.4M | 0.0 | 7.7M | 26.7M | 4.9M | 6.8M | -404K | 46.6M | 5.7M | 2M | 0.0 | 3M | 10.2M | 0.0 | 3.5M | 0.0 | 3.3M | 875.0 | |
-12K | -11K | -15K | -16K | -31K | -272K | 9.7M | -196K | -608K | -5.2M | 2.3M | 2.3M | -108.4K | -86.1K | -81.7K | -62.6K | -78.5K | -74.6K | 0.0 | |
-251K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -404K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -8.2K | (0.0) | (0.0) | (0.0) | -959.6K | (0.0) | |
0.0 | -52K | -75K | -77K | 9.4M | 4.1M | 388K | 510K | 3M | 258.7K | 79.8K | 364.3K | 1.8M | 160.6K | 2.6M | 1.2M | 0.0 | 8K | 0.0 | |
7M | 5.4M | -90K | 7.7M | 36.1M | 8.7M | 16.9M | -90K | 48.9M | 754.3K | 4.3M | 2.7M | 4.6M | 10.3M | 2.5M | 4.6M | -78.5K | 3.2M | 875.0 | |
CASH FLOW SUMMARY | |||||||||||||||||||
20.1M | 17.3M | 6.9M | -7.8M | 11.5M | -2.1M | -3.8M | -22.8M | 43.7M | -3.9M | 1.6M | 1.7M | 1.7M | 99.8K | -1.8M | 1.8M | -654.1K | 821.7K | -37.6K | |
44.7M | 27.3M | 20.4M | 28.2M | 16.7M | 18.8M | 22.6M | 45.4M | 1.6M | 5.5M | 4M | 2.3M | 520K | 420.2K | 2.2M | 471.4K | 1.1M | 303.8K | 38.2K | |
64.8M | 44.7M | 27.3M | 20.4M | 28.2M | 16.7M | 18.8M | 22.6M | 45.4M | 1.6M | 5.5M | 4M | 2.3M | 520K | 420.2K | 2.2M | 471.4K | 1.1M | 580.0 | |
13.1M | 11.9M | 7M | -15.4M | -24.6M | -10.7M | -21.2M | -22.4M | -11.2M | -4.7M | -2.8M | -2.8M | -4.1M | -10.2M | -4.3M | -2.9M | -580.7K | -2.4M | -38.5K |
NAGE - Filing history and reports
No SEC filings available for NAGE
Continue your NAGE research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.